Cite
Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma.
MLA
Lian, B., et al. “Phase II Clinical Trial of Neoadjuvant Anti-PD-1 (Toripalimab) Combined with Axitinib in Resectable Mucosal Melanoma.” Annals of Oncology, vol. 35, no. 2, Feb. 2024, pp. 211–20. EBSCOhost, https://doi.org/10.1016/j.annonc.2023.10.793.
APA
Lian, B., Li, Z., Wu, N., Li, M., Chen, X., Zheng, H., Gao, M., Wang, D., Sheng, X., Tian, H., Si, L., Chi, Z., Wang, X., Lai, Y., Sun, T., Zhang, Q., Kong, Y., Long, G. V., Guo, J., & Cui, C. (2024). Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma. Annals of Oncology, 35(2), 211–220. https://doi.org/10.1016/j.annonc.2023.10.793
Chicago
Lian, B., Z. Li, N. Wu, M. Li, X. Chen, H. Zheng, M. Gao, et al. 2024. “Phase II Clinical Trial of Neoadjuvant Anti-PD-1 (Toripalimab) Combined with Axitinib in Resectable Mucosal Melanoma.” Annals of Oncology 35 (2): 211–20. doi:10.1016/j.annonc.2023.10.793.